Evidence map›Paper›PMID 38586227›Full record

ArticleCureus2024

Unraveling the Mystery of Desmoid Tumors: Insights From a Moroccan Tertiary Center.

Salma Najem, Soukaina Bekkouche, Amine Benslimane, Sarah Naciri, Hanane Inrhaouen, Ibrahim El Ghissassi, Saber Boutayeb, Hind Mrabti, Hassan Errihani

Abstract read
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Salma NajemDepartment of Medical Oncology, National Institute of Oncology, Faculty of Medicine, Mohammed V Faculty, Rabat, MAR.
Soukaina BekkoucheDepartment of Medical Oncology, National Institute of Oncology, Faculty of Medicine, Mohammed V Faculty, Rabat, MAR.
Amine BenslimaneDepartment of Medical Oncology, National Institute of Oncology, Faculty of Medicine, Mohammed V Faculty, Rabat, MAR.
Sarah NaciriDepartment of Medical Oncology, National Institute of Oncology, Faculty of Medicine, Mohammed V Faculty, Rabat, MAR.
Hanane InrhaouenDepartment of Medical Oncology, National Institute of Oncology, Faculty of Medicine, Mohammed V Faculty, Rabat, MAR.
Ibrahim El GhissassiDepartment of Medical Oncology, National Institute of Oncology, Faculty of Medicine, Mohammed V Faculty, Rabat, MAR.
Saber BoutayebDepartment of Medical Oncology, National Institute of Oncology, Faculty of Medicine, Mohammed V Faculty, Rabat, MAR.
Hind MrabtiDepartment of Medical Oncology, National Institute of Oncology, Faculty of Medicine, Mohammed V Faculty, Rabat, MAR.
Hassan ErrihaniDepartment of Medical Oncology, National Institute of Oncology, Faculty of Medicine, Mohammed V Faculty, Rabat, MAR.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Desmoid tumors (DTs) are rare, aggressive malignancies developing from clonal fibroblastic proliferation originating from soft tissues. Despite their low metastatic potential, their invasiveness towards neighboring organs and a high recurrence rate contribute significantly to morbidity and mortality, thereby impacting the quality of life of patients. Several therapeutic options are available, but standardized protocols are lacking. In this study, we reviewed 14 cases of DT retrospectively over a period of 15 years, from September 2008 to December 2023. The most prevalent tumor locations were in the extremities, and the majority of patients were female. We identified risk factors in two patients, those being surgical trauma and familial adenomatous polyposis (FAP). Half of the patients underwent surgery for DT, and two received salvage radiotherapy. Systemic therapy was used in the first and second lines and comprised of chemotherapy, endocrine therapy, and non-steroidal anti-inflammatory drugs (NSAI). Active surveillance was proposed in three patients. This is the first retrospective study to assess the characteristics of DT in Moroccan patients in a tertiary care setting. It aims to shed light on the challenges faced in treating these rare tumors in the context of a lack of therapeutic standardization.

Indexed as

active surveillancechemotherapydesmoid tumorssurgeryy secretase inhibitor

Identifiers

PMID38586227
PMCPMC10999233

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.